This is a working overview of human growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-28. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== General SPPS procedure === Stepwise SPPS proceeds from the C-terminal amino acid residue of the target peptide chain covalently attached to the resin support. Each amino acid to be coupled to the N-terminus of the resin bound nascent peptide chain must be protected on its alpha amino group using protecting groups such as Boc (acid-labile) or Fmoc (base-labile), depending on the protection strategy used (see below). The general SPPS procedure is one of repeated cycles of alternate N-terminal deprotection and peptide bond-forming 'coupling' reactions. The resin is washed with organic solvent between each chemical reaction step. Reactions in SPPS are conducted as follows:
Both laser and conventional surgeries are performed to treat glaucoma. Surgery is the primary therapy for those with congenital glaucoma. Generally, these operations are a temporary solution, as there is not yet a cure for glaucoma.
== Histopathology == Although the exact cause of this condition is not known, it is an inflammatory disorder characterized by collagen degeneration, combined with a granulomatous response. It always involves the dermis diffusely, and sometimes also involves the deeper fat layer. Commonly, dermal blood vessels are thickened (Microangiopathy). It can be precipitated by local trauma, though it often occurs without any injury. As a metabolically driven skin disorder, the pathology is characterized by poor intracellular glucose utilization leading to metabolically stressed fibroblasts. Despite an increased GLUT-1 response, fibroblasts in NL fail to produce normal collagen, weakening and breaking down the skin's structure. Vascular impairments reduce oxygen and nutrient circulation, creating hypoxia and tissue breakdown.
Sources: en.wikipedia.org
This version of the song, which features Maynard James Keenan (from Tool and A Perfect Circle) and guitarist John Frusciante (of the Red Hot Chili Peppers), was praised by Aicher as "Dark, brooding, sad, and twitchy".
After passing the OBBBA, Congress needed to approve a new spending bill to fund the federal government beyond October 1, 2025, when the previous budget expired. The 53 Republican senators had to either eliminate the filibuster or convince at least seven Democrats to join them in order to reach the 60-vote supermajority required to advance their proposal. Most Democrats opposed the Republican plan and requested a compromise that would extend the healthcare subsidies cut by the OBBBA. The resulting stalemate triggered the 2025 United States federal government shutdown, which became the longest government shutdown in U.S. history.
== Insect-based pet food products on the market == As of August 5, 2021, AAFCO (Association of American Feed Control Officials) has voted to include adult dogs in the ingredient definition for whole dried black soldier fly larvae and black soldier fly larvae meal. This approval allows for the sale of BSF based dog food and treats in the United States. As of June 2023, according to a review of the market by leading BSF producer Protix there are over 43 brands worldwide marketing insect-based pet foods. 35 of these are in Europe. An example of a European brand developing complete dog and cat diets and treats using BSF in European, Asian and North American markets is YORA, another example of a brand making BSF treats in the US and Canada is ALT-PRO Advantage (formerly known as HOPE Pet Food).
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.